Clinical Trials for Cervical Cancer

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locoregional recurrent, non-nasopharyngeal HNSCC (M0), CPS ≥1, PD-1/PD-L1–naïve, with at least one lesion accessible for light activation are randomized to pembrolizumab plus ASP-1929 photoimmunotherapy (cetuximab–IRDye700DX conjugate targeting EGFR, activated by 690 nm light) versus pembrolizumab-based standard of care (mono or with chemo). The study tests whether adding EGFR-targeted photoimmunotherapy to PD-1 blockade improves overall survival; key exclusions include CNS metastases, significant autoimmune disease, and conditions contraindicating photosensitive procedures.

ClinicalTrials.gov ID: NCT06699212

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic salivary gland cancers enroll into two cohorts: adenoid cystic carcinoma with recent progression, or non-ACC (SDC, intermediate/high-grade adenocarcinoma NOS, MEC) after ≤3 prior palliative chemotherapies (HER2+ must have received HER2 therapy), ECOG 0–1. Treatment is sacituzumab govitecan, a Trop-2–targeted antibody–drug conjugate delivering SN-38, given IV on days 1 and 8 of 21-day cycles; safety and efficacy are assessed separately by histology.

ClinicalTrials.gov ID: NCT05884320

Phase 1b Study of TMV Vaccine Therapy Alone and TMV Vaccine Plus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic HNSCC (oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, sinonasal, or unknown primary) after ≥2 prior systemic lines and amenable to salvage surgery receive an autologous tumor membrane vesicle (TMV) vaccine derived from their resected tumor, alone or combined with pembrolizumab. TMV is a personalized intradermal vaccine presenting native tumor membrane antigens/neoantigens to prime T-cell responses; the combination adds anti–PD-1 checkpoint blockade.

ClinicalTrials.gov ID: NCT06868433

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-refractory recurrent/metastatic HNSCC (oral cavity, oropharynx, larynx, hypopharynx), PD-L1 CPS ≥1, ECOG 0–2, and no prior systemic therapy for R/M disease are randomized to pembrolizumab alone vs pembrolizumab plus cetuximab. Pembrolizumab is an anti–PD-1 antibody; cetuximab is an anti-EGFR antibody, with the combination tested to enhance efficacy in this setting.

ClinicalTrials.gov ID: NCT06589804

A Phase II Trial of Lovastatin and Pembrolizumab in Patients with RM HNSCC (LAPP)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma (ECOG 0–1) not candidates for salvage surgery receive pembrolizumab plus oral lovastatin; prior checkpoint inhibitor use and current statin therapy are excluded. Pembrolizumab is an anti–PD-1 antibody, and lovastatin (HMG‑CoA reductase inhibitor) is added to potentially enhance antitumor immunity via mevalonate pathway inhibition.

ClinicalTrials.gov ID: NCT06636734

Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic nasopharyngeal carcinoma after platinum–gemcitabine and prior PD‑1/L1 therapy (up to two prior lines; ECOG 0–2; treated/stable brain mets allowed) are randomized to nivolumab (PD‑1) plus ipilimumab (CTLA‑4) with or without cabozantinib, a multikinase inhibitor of MET/VEGFR2/AXL. Aims to determine whether adding cabozantinib improves outcomes versus dual checkpoint blockade alone.

ClinicalTrials.gov ID: NCT05904080

Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or metastatic nasopharyngeal carcinoma, systemic treatment–naïve for the metastatic setting and with measurable disease, receive induction gemcitabine/platinum plus toripalimab (anti–PD-1), with optional switch to carboplatin from cycle 2, followed by maintenance toripalimab. Excludes candidates for curative local therapy, prior systemic therapy for R/M disease, early recurrence after chemoradiation (<6 months), rapidly progressive disease, and active/untreated CNS metastases.

ClinicalTrials.gov ID: NCT06457503

A Randomized Phase III TriaL Comparing SingLe- Versus Multi-Fraction Spine STereotActic Radiosurgery for Patients With Spinal Metastases (ALL-STAR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic disease to 1–3 spinal sites (cervical/thoracic/lumbar; ECOG 0–2; no overlapping radiation, prior surgery at the site, myeloma/lymphoma, major neurologic deficits, or high SINS) are randomized to spine SRS delivered as 22 Gy × 1 versus 14 Gy × 2. The trial compares 1-year local control, safety, pain, vertebral fracture risk, and patient-reported outcomes between these standard SBRT regimens.

ClinicalTrials.gov ID: NCT06173401

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling children and adults with NTRK1/2/3 fusion–positive differentiated thyroid cancer (post-thyroidectomy) with CT-evaluable pulmonary metastases and no prior RAI or systemic therapy. Patients receive a 6-month lead-in of larotrectinib (selective TRKA/B/C inhibitor) followed by radioactive iodine (131I), aiming to enhance RAI avidity and induce complete pulmonary responses.

ClinicalTrials.gov ID: NCT05783323

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral belzutifan, a selective HIF-2α inhibitor, for adults with recurrent or persistent clear cell ovarian carcinoma (≥50% clear cell if mixed) with measurable disease after at least one prior platinum regimen; prior bevacizumab and immunotherapy allowed and treated/stable brain metastases permitted. Patients receive daily belzutifan in 28-day cycles until progression/toxicity, with primary endpoints of ORR and 6-month PFS; class-toxicities include anemia and hypoxia.

ClinicalTrials.gov ID: NCT06677190